Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: A pilot study

Cancer

Volumn 82, Issue 5, 1998, Pages 827-835

  Ikeda, Kenji ^a   Saitoh, Satoshi ^a   Suzuki, Yoshiyuki ^a   Kobayashi, Masahiro ^a   Tsubota, Akihito ^a   Fukuda, Mizuho ^a   Koida, Isao ^a   Arase, Yasuji ^a   Chayama, Kazuaki ^a   Murashima, Naoya ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Carcinogenesis; Cirrhosis; Hepatitis B virus; Hepatitis B virus DNA; Hepatocellular carcinoma; Interferon; Prevention

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; LYMPHOBLAST INTERFERON; RECOMBINANT ALPHA2A INTERFERON; VIRUS DNA;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER PREVENTION; CHILL; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; FEMALE; FEVER; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; PRIORITY JOURNAL; PSYCHOSIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 0032032927     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980301)82:5<827::AID-CNCR5>3.0.CO;2-G     Document Type: Article

References (33)

1. Parkin DM, Stjernsward J, Muir CS. Estimates of worldwide frequency of twelve major cancers. Bull World Health Organ 1984;62:163-82.
2. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology 1986;6:729-38.
3. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan: clinicopathological features and results of surgical treatment. Ann Surg 1990;211:277-87.
4. Prince AM, Szmuness W, Michon J, Desmaille J, Diebolt G, Linhard J, et al. A case-control study of the association between primary liver cancer and hepatitis B infection in Senegal. Int J Cancer 1975;16:376-83.
5. Ohnishi K, Iida S, Iwama S, Goto N, Nomura F, Takashi M, et al. The effect of chronic habitual alchohol intake on the development of liver cirrhosis and hepatocellular carcinoma. Relation to hepatitis B surface antigen carriage. Cancer 1982;49:672-7.
6. Lam KC, Yu MC, Leung JWC, Henderson BE. Hepatitis B virus and cigarette smoking: risk factors for hepatocellular carcinoma in Hong Kong. Cancer Res 1982;42:5246-8.
7. Shafritz D, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. N Engl J Med 1981;305:1067-73.
8. Brechot C, Degos F, Lugassy C, Thiers V, Zafrani S, Franco D, et al. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med 1981;312:270-6.
9. Zaman SN, Melia WM, Johnson RD, Portmann BC, Johnson PJ, Williams R. Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet 1985;i:1357-60.
10. Austin H, Delzell E, Grufferman S, Levine R, Morrison AS, Stolley PD, et al. A case-control study of hepatocellular carcinoma and the hepatitis B virus, cigarette smoking, and alcohol consumption. Cancer Res 1985;46:962-6.
11. Villa E, Baldini GM, Pasquinelli C, Melegari M, Cariani E, Di Chirico G, et al. Risk factors for hepatocellular carcinoma in Italy. Male sex, hepatitis B virus, non-A non-B infection, and alcohol. Cancer 1988;62:611-5.
12. Weimar W, Heijtink RA, Kate FJ, Schalm SW, Masurel N, Schellekens H, et al. Double blind study of leukocyte interferon administration in chronic HBsAg positive hepatitis. Lancet 1980;1:336-8.
13. Alexander GJ, Fagen EA, Guarner P, Rolando N, Brahm J, Eddleston AL, et al. A controlled trial of 6 months thrice weekly lymphoblastoid interferon versus no therapy in chronic hepatitis B virus infection. J Hepatol 1986;3(Suppl 2):S183-8.
14. Dusheiko GM, Paterson AC, Pitcher L, Kassianides C, DiBisceglie AM, Song E, et al. Recombinant leukocyte interferon treatment of chronic hepatitis B. J Hepatol 1986;3(Suppl 2):S199-207.
15. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981;94:744-8.
16. Lok AS, Weller IV, Karrayanis P, Brown D, Fowler MJ, Monjardino J, et al. Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication. Liver 1984;4:45-9.
17. Koreman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114:629-34.
18. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664-75.
19. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995;22:1863-73.
20. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrica 1982;69:553-66.
21. Hendricks DA, Stowe BJ, Hoo BS, Kolberg J, Irvine BD, Neuwald PD, et al. Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay. Am J Clin Pathol 1995;104:537-46.
22. Kaplan EL, Meier P. Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-81.
23. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:248-75.
24. SAS Institute Inc. SAS/STAT user's guide. Release 6. 3rd edition. Cary, NC: SAS Institute Inc., 1988.
25. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 cases with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
26. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-1801.
27. Krogsgaard K, Bindslev N, Christensen E, Craxi A, Schlichting P, Schalm S, et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patients data from 10 clinical controlled trials. J Hepatol 1994;21:646-55.
28. Janssen HL, Schoenmaker Weber YA, Kruining H, Schalm SW, Heijtink RA. Quantitative assessment of hepatitis B virus DNA in chronic hepatitis B: comparison of two solution hybridization assays. J Med Virol 1993;40:307-12.
29. Ranki M, Schatzl HM, Zachoval R, Uusi Oukari M, Lehtovaara P. Quantification of hepatitis B virus DNA over a wide range from serum for studying viral replicative activity in response to treatment and in recurrent infection. Hepatology 1995;21:1492-9.
30. Garcia F Jr., Garcia F, Bernal MC, Leyva A, Piedrola G, Maroto MC. Evaluation of enzyme immunoassay for hepatitis B virus DNA based on anti-double-stranded DNA. J Clin Microbiol 1995;33:413-5.
31. Nevens F, Goubau P, Van Eyken P, Desmyter J, Desmet V, Fevery J. Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha. Liver 1993;13:15-9.
32. Dunk AA, Ikeda T, Pignatelli M, Thomas HC. Human lymphoblastoid interferon: in vitro and in vivo studies in hepatocellular carcinoma. J Hepatol 1986;2:419-29.
33. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993;17:389-94.